Novo Nordisk Shares Face Geopolitical Headwinds from US Tariff Threat
Published on 01/19/2026 at 14:49 | Redaktion boerse-global.de
Novo Nordisk investors are navigating a volatile mix of robust commercial performance and emerging political risk. While recent prescription data for a key new product exceeded expectations, a new trade dispute initiated by the United States against Denmark now casts a shadow over future margins and supply chain stability for the pharmaceutical giant.
The market sentiment shifted sharply between Friday and Monday. The week ended on a high note following the release of IQVIA data showing a powerful debut for Novo Nordisk’s oral Wegovy tablet in the crucial US market. In the first four days of its launch, approximately 3,071 prescriptions were filled in US pharmacies. This significantly outpaced Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
